Results 11 to 20 of about 180 (117)

Performing a physiologically relevant test for cladribine tablets

Разработка и регистрация лекарственных средств
Introduction. The introduction of devices – analogues of GIS (hereinafter–- Gastro-intestinal simulator) is one of the current ways to develop in-vitro assessment of the quality of solid dosage forms.
P. A. Losenkova, D. D. Gvozdev, A. V. Suvorova, Yu. V. Medvedev, V. S. Shcherbakova, Yu. G. Kazaishvili, K. Ya. Zaslavskaya, A. M. Poluyanov, I. E. Shohin   +8 more
doaj   +2 more sources

Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design

Therapeutic Advances in Neurological Disorders
Background: Individual disease modifying therapies approved for multiple sclerosis (MS) have limited effectiveness and potentially serious side effects, especially when administered over long periods.
Peter V. Sguigna, Rehana Z. Hussain, Annette Okai, Kyle M. Blackburn, Lauren Tardo, Mariam Madinawala, Julie Korich, Lori A. Lebson, Jeffrey Kaplan, Amber Salter, Navid Manouchehri, Olaf Stuve   +11 more
doaj   +3 more sources

Cladribine tablets in the new multiple sclerosis era

Therapeutic Advances in Neurological Disorders
Multiple sclerosis (MS) is an autoimmune condition characterized by inflammatory demyelination that leads to irreversible neurological damage within the central nervous system (CNS). This review examines the therapeutic potential and clinical efficacy of
Fabio Buttari, Ettore Dolcetti, Francesca Romana Rizzo, Caterina Rizzi, Gianluca Lauritano, Angela Borrelli, Federica Azzolini, Roberta Fantozzi, Francesco Assogna, Antonella Conte, Diego Centonze   +10 more
doaj   +3 more sources

Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review

Neurology and Therapy, 2023
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system, characterized by chronic, inflammatory, demyelinating, and neurodegenerative processes. MS management relies on disease-modifying drugs that suppress/modulate the immune
Federico Carlini, Valeria Lusi, Caterina Rizzi, Francesco Assogna, Alice Laroni   +4 more
doaj   +4 more sources

The effect of cladribine tablets on intrathecal inflammation in relapsing-remitting multiple sclerosis

Journal of Neuroinflammation
Background To investigate the intrathecal effect of cladribine tablets on cerebrospinal fluid (CSF) inflammatory proteomic profile, cortical lesions (CLs), paramagnetic rim lesions (PRLs) number and cognition after 2 years of treatment. Results Forty-two
Damiano Marastoni, Chiara Eccher, Alessio Signori, Daniela Anni, Matteo Foschi, Francesco Crescenzo, Valentina Mazziotti, Federica Virla, Monica Sicchieri, Ermanna Turano, Agnese Tamanti, Valentina Camera, Stefano Ziccardi, Giulia Zanetti, Francesca Benedetta Pizzini, Silvia Martini, Anna Fratucello, Bruno Bonetti, Maria Pia Sormani, Massimiliano Calabrese   +19 more
doaj   +6 more sources

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets

Current Neuropharmacology, 2022
: COVID 19 pandemic and mass vaccination campaigns have revealed the situation of the most vulnerable patients. In this work, we focused our attention to patients who have Multiple Sclerosis (MS), particularly in treatment with cladribine tablets, trying to understand if and when it is possible to administer the vaccine successfully.
Moiola, Lucia, Riva, Agostino, Nicoletti, Ferdinando, Uccelli, Antonio, Salvetti, Marco, Battistini, Luca, Furlan, Roberto   +6 more
openaire   +5 more sources

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review [PDF]

Drugs, 2020
Cladribine is a purine nucleoside analog initially developed in the 1970s as a treatment for various blood cancers. Due to the molecule's ability to preferentially reduce T and B lymphocytes, it has been developed into an oral formulation for the treatment of multiple sclerosis (MS).
Rammohan, Kottil, Coyle, Patricia K., Sylvester, Elke, Galazka, Andrew, Dangond, Fernando, Grosso, Megan, Leist, Thomas P.   +6 more
openaire   +2 more sources

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review

Neurology and Therapy, 2022
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by inflammation and demyelination for which there is currently no cure; therefore, the aim of therapy is to reduce the risk of relapse and disability progression. The treatment options for MS have increased greatly in recent years with the development of several disease ...
Gavin Giovannoni, Joela Mathews
openaire   +2 more sources

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis [PDF]

Clinical Pharmacokinetics, 2018
Cladribine Tablets (MAVENCLAD®) are used to treat relapsing multiple sclerosis (MS). The recommended dose is 3.5 mg/kg, consisting of 2 annual courses, each comprising 2 treatment weeks 1 month apart. We reviewed the clinical pharmacology of Cladribine Tablets in patients with MS, including pharmacokinetic and pharmacometric data.
Hermann, Robert, Karlsson, Mats O, Novakovic, Ana M., Terranova, Nadia, Fluck, Markus, Munafo, Alain   +5 more
openaire   +3 more sources

Cladribine Tablets: A Review in Relapsing MS [PDF]

CNS Drugs, 2018
Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS) pathogenesis. Cladribine tablets (Mavenclad®) represent the first short-course oral disease-modifying drug (DMD) for use in MS.
openaire   +2 more sources